IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v43y2020i9d10.1007_s40264-020-00945-0.html
   My bibliography  Save this article

Information Visualization Platform for Postmarket Surveillance Decision Support

Author

Listed:
  • Jonathan Spiker

    (Johns Hopkins University School of Medicine)

  • Kory Kreimeyer

    (Johns Hopkins University School of Medicine)

  • Oanh Dang

    (Center for Drug Evaluation and Research, US FDA)

  • Debra Boxwell

    (Center for Drug Evaluation and Research, US FDA)

  • Vicky Chan

    (Center for Drug Evaluation and Research, US FDA)

  • Connie Cheng

    (Center for Drug Evaluation and Research, US FDA)

  • Paula Gish

    (Center for Drug Evaluation and Research, US FDA)

  • Allison Lardieri

    (Center for Drug Evaluation and Research, US FDA)

  • Eileen Wu

    (Center for Drug Evaluation and Research, US FDA)

  • Suranjan De

    (Center for Drug Evaluation and Research, US FDA)

  • Jarushka Naidoo

    (Johns Hopkins University School of Medicine)

  • Harold Lehmann

    (Johns Hopkins University School of Medicine)

  • Gary L. Rosner

    (Johns Hopkins University School of Medicine)

  • Robert Ball

    (Center for Drug Evaluation and Research, US FDA)

  • Taxiarchis Botsis

    (Johns Hopkins University School of Medicine)

Abstract

Introduction The US FDA receives more than 2 million postmarket reports each year. Safety Evaluators (SEs) review these reports, as well as external information, to identify potential safety signals. With the increasing number of reports and the size of external information, more efficient solutions for data integration and decision making are needed. Objectives The aim of this study was to develop an interactive decision support application for drug safety surveillance that integrates and visualizes information from postmarket reports, product labels, and biomedical literature. Methods We conducted multiple meetings with a group of seven SEs at the FDA to collect the requirements for the Information Visualization Platform (InfoViP). Using infographic design principles, we implemented the InfoViP prototype version as a modern web application using the integrated information collected from the FDA Adverse Event Reporting System, the DailyMed repository, and PubMed. The same group of SEs evaluated the InfoViP prototype functionalities using a simple evaluation form and provided input for potential enhancements. Results The SEs described their workflows and overall expectations around the automation of time-consuming tasks, including the access to the visualization of external information. We developed a set of wireframes, shared them with the SEs, and finalized the InfoViP design. The InfoViP prototype architecture relied on a javascript and a python-based framework, as well as an existing tool for the processing of free-text information in all sources. This natural language processing tool supported multiple functionalities, especially the construction of time plots for individual postmarket reports and groups of reports. Overall, we received positive comments from the SEs during the InfoViP prototype evaluation and addressed their suggestions in the final version. Conclusions The InfoViP system uses context-driven interactive visualizations and informatics tools to assist FDA SEs in synthesizing data from multiple sources for their case series analyses.

Suggested Citation

  • Jonathan Spiker & Kory Kreimeyer & Oanh Dang & Debra Boxwell & Vicky Chan & Connie Cheng & Paula Gish & Allison Lardieri & Eileen Wu & Suranjan De & Jarushka Naidoo & Harold Lehmann & Gary L. Rosner &, 2020. "Information Visualization Platform for Postmarket Surveillance Decision Support," Drug Safety, Springer, vol. 43(9), pages 905-915, September.
  • Handle: RePEc:spr:drugsa:v:43:y:2020:i:9:d:10.1007_s40264-020-00945-0
    DOI: 10.1007/s40264-020-00945-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-020-00945-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-020-00945-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:43:y:2020:i:9:d:10.1007_s40264-020-00945-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.